URGN Key Statistics, Chart & Performance
The current stock price of URGN is 20 USD. In the past month the price decreased by -14.53%. In the past year, price increased by 95.31%.
URGN Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to URGN. When comparing the yearly performance of all stocks, URGN is one of the better performing stocks in the market, outperforming 92.74% of all stocks.
URGN Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to URGN. Both the profitability and financial health of URGN have multiple concerns.
URGN Financial Highlights
Over the last trailing twelve months URGN reported a non-GAAP Earnings per Share(EPS) of -3.46. The EPS decreased by -9.84% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -88.97% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
URGN Forecast & Estimates
14 analysts have analysed URGN and the average price target is 35.96 USD. This implies a price increase of 79.77% is expected in the next year compared to the current price of 20.
For the next year, analysts expect an EPS growth of 0.39% and a revenue growth 23.18% for URGN
URGN Ownership
About URGN
Company Profile
UroGen Pharma Ltd. is a biopharmaceutical company, which engages in developing and commercializing innovative solutions that treat urothelial and specialty cancers. The firm is engaged in building solutions for cancers and urologic diseases. UroGen has developed RTGelTM reverse-thermal hydrogel, a proprietary sustained release, hydrogel-based platform technology that has the potential to improve therapeutic profiles of existing drugs. Its lead product candidates include MitoGel and VesiGel are formulated using its proprietary reverse thermally triggered hydrogel, or RTGel, technology. MiroGel ( UGN-101) is a sustained release formulation of the chemotherapy agent Mitomycin C for the treatment of low-grade upper tract urothelial carcinoma, an urothelial cancer in the upper tract. VesiGel (UGN-102) is a sustained release formulation of a high dose Mitomycin C for the treatment of low grade non-muscle invasive bladder cancer (LG-NMIBC).
Company Info
UROGEN PHARMA LTD
9 Ha'ta'asiya St
Ra'anana 08540 IL
CEO: Elizabeth Barrett
Employees: 287
Phone: 97297707601
UROGEN PHARMA LTD / URGN FAQ
What does URGN do?
UroGen Pharma Ltd. is a biopharmaceutical company, which engages in developing and commercializing innovative solutions that treat urothelial and specialty cancers. The firm is engaged in building solutions for cancers and urologic diseases. UroGen has developed RTGelTM reverse-thermal hydrogel, a proprietary sustained release, hydrogel-based platform technology that has the potential to improve therapeutic profiles of existing drugs. Its lead product candidates include MitoGel and VesiGel are formulated using its proprietary reverse thermally triggered hydrogel, or RTGel, technology. MiroGel ( UGN-101) is a sustained release formulation of the chemotherapy agent Mitomycin C for the treatment of low-grade upper tract urothelial carcinoma, an urothelial cancer in the upper tract. VesiGel (UGN-102) is a sustained release formulation of a high dose Mitomycin C for the treatment of low grade non-muscle invasive bladder cancer (LG-NMIBC).
Can you provide the latest stock price for UROGEN PHARMA LTD?
The current stock price of URGN is 20 USD.
What is the dividend status of UROGEN PHARMA LTD?
URGN does not pay a dividend.
How is the ChartMill rating for UROGEN PHARMA LTD?
URGN has a ChartMill Technical rating of 2 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
What is the analyst forecast for URGN stock?
14 analysts have analysed URGN and the average price target is 35.96 USD. This implies a price increase of 79.77% is expected in the next year compared to the current price of 20.
What is the employee count for URGN stock?
UROGEN PHARMA LTD (URGN) currently has 287 employees.
What is UROGEN PHARMA LTD worth?
UROGEN PHARMA LTD (URGN) has a market capitalization of 936.20M USD. This makes URGN a Small Cap stock.